Skip to main content
CYBIN INC. logo

CYBIN INC. — Investor Relations & Filings

Ticker · CYBN ISIN · CA23256X1006 LEI · 549300NTYWN4CVYSCN32 US Manufacturing
Filings indexed 379 across all filing types
Latest filing 2026-01-02 Regulatory Filings
Country CA Canada
Listing US CYBN

About CYBIN INC.

https://www.cybin.com

Cybin Inc. is a late-stage clinical neuropsychiatry company dedicated to revolutionizing mental healthcare by developing novel psychedelic-based therapeutics. The company utilizes proprietary drug discovery platforms, innovative drug delivery systems, and a deuterated chemical process to engineer next-generation, patent-protected drug candidates from tryptamine-based scaffolds. Its lead programs include CYB003, a deuterated psilocybin analog for Major Depressive Disorder (MDD) that has received FDA Breakthrough Therapy Designation, and CYB004 for the treatment of Generalized Anxiety Disorder (GAD). Cybin aims to create safer, more effective, and commercially scalable treatments for various mental health conditions.

Recent filings

Filing Released Lang Actions
FORM 8-A12B
Regulatory Filings
2026-01-02 English
NOTIFICATION OF REMOVAL FROM LISTING
Delisting Announcement
2026-01-02 English
FORM 6-K
Foreign Filer Report
2025-12-31 English
FORM 6-K
Foreign Filer Report
2025-12-30 English
FORM SUPPL
Regulatory Filings
2025-12-30 English
6-K
Foreign Filer Report
2025-12-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.